^
    Apply
    Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China) (NCT03722420)
    Phase 3
    Il-Yang Pharm. Co., Ltd.
    Active, not recruiting
    Last update posted :
    03/06/2024
    Initiation :
    12/28/2018
    Primary completion :
    03/03/2023
    Completion :
    06/30/2025
    ABL1 • BCR
    |
    imatinib • Supect (radotinib)
    A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs (NCT03459534)
    Phase 3
    Il-Yang Pharm. Co., Ltd.
    Recruiting
    Last update posted :
    10/13/2023
    Initiation :
    06/25/2018
    Primary completion :
    01/29/2025
    Completion :
    04/01/2025
    ABL1 • BCR
    |
    imatinib • Supect (radotinib)